Avantor (AVTR)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$14.97-1.45%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · AVTR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -4.0% |
| Our one-year growth estimate | diamond | 2.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 6.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers · Company calendar date is not available
AVTR — President transition
Dated 2026-08-27
Executive Vice President — Benoit Gourdier: The filing confirms the departure of an Executive Vice President with a defined end date and severance, representing a genuine loss of a senior officer but not a sudden shock to the top leadership (CEO/CFO).
Why it matters: Revenue growth is key to Avantor’s strategy. A decline signals ongoing challenges.
Worry ifQ2 revenue growth reported below 0% year over year.
Less concerning ifQ2 revenue growth reported above 0% year over year.
Why it matters: A drop in operating income margin means profits are getting worse.
Worry ifOperating income margin is less than 6.3%.
Less concerning ifOperating income margin is more than 6.3%.
Why it matters: The new EVP's impact on the BMP segment could drive growth and operational improvements.
Supportive ifGood news on BMP segment growth under Ludovic Brellier's leadership.
Worry ifBad news on BMP segment performance after the transition.
Why it matters: A higher margin would show that management is working to make more money.
Supportive ifThe operating income margin goes above 7.5% in Q3 2026.
Worry ifOperating income margin falls below 7.2% in Q3 2026.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$162 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $415 loss on $10,000 · 4.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,250 loss on $10,000 · 52.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better organic sales growth shows Avantor is doing well and meeting demand.
Supportive ifQ2 organic sales growth is better than -4.1%. This shows a positive trend.
Worry ifQ2 organic sales growth worsens or remains at -4.1% or lower.
Why it matters: New leaders may help the segment grow and improve operations.
Supportive ifLook for sales growth in Bioscience & Medtech under Ludovic Brellier in two quarters.
Worry ifSales growth in Bioscience & Medtech stays flat or drops with new leaders.
Why it matters: Operating income is important for making money. A rise shows better cost control.
Supportive ifOperating income in Q2 is over $99.5 million.
Worry ifOperating income in Q2 falls below $99.5 million.
Why it matters: The new CFO's plan will affect Avantor's money strategy. Clear direction is important.
Watch forThe new CFO shares a clear plan to boost financial results.
Also watch forThe new CFO provides vague or no strategic direction.
Why it matters: Paying off debt shows Avantor wants to make its balance sheet stronger.
Supportive ifAvantor repays more than $112.1 million in debt in Q3.
Worry ifNo debt repayment or an increase in total debt.
Why it matters: If the Revival initiative works, it could help the company grow and improve.
Supportive ifGood news about the Revival initiative's progress came out in Q2.
Worry ifNo big updates or negative news on the Revival initiative in Q2.
Why it matters: Positive revenue growth shows that Avantor is growing its sales well.
Supportive ifQ3 organic revenue growth is above 0%.
Worry ifQ3 organic revenue growth is still negative.
Why it matters: A smooth CFO change is key for financial stability and strategy.
Watch forAnnouncement of a new CFO appointed before June 24, 2026.
Also watch forNo new CFO appointed by June 24, 2026.
Why it matters: Paying off debt shows strong cash flow and good financial health.
Supportive ifCompany repays more than $112.1 million in debt in Q3.
Worry ifCompany does not repay any debt in Q3.
Why it matters: Doing well could improve customer experience and boost growth.
Watch forManagement reports good progress in the Revival program with clear gains.
Also watch forManagement says the Revival program is late or not meeting its goals.